Chicago

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• HIV9 trials
• COPD3 trials
• Colorectal cancer2 trials
• Lung cancer2 trials
• Asthma1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• Melanoma1 trial
• Multiple myeloma1 trial
• Ovarian cancer1 trial
• Systemic sclerosis (scleroderma)1 trial
• and 1 more

Phase

• Phase 311 trials
• Phase 25 trials
• Phase 13 trials
• Phase 2/31 trial

Status

• Active, not recruiting10 trials
• Recruiting6 trials
• Completed5 trials

Lead sponsor

• GlaxoSmithKline9 trials
• ViiV Healthcare9 trials
• Tesaro, Inc.3 trials

Running trials

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

  Contact: Mariam Aziz (principal investigator)

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

  Contact: Aniruddha Hazra (principal investigator)

• Active, not recruiting

  A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

  NCT07053384· Phase 1· ViiV Healthcare· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  NCT06961214· Phase 3· GlaxoSmithKline· Source

  Contact: Thomas Wade (principal investigator)

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

  Contact: Daniel Meza (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

  NCT06741397· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· GlaxoSmithKline· Source

  Contact: Bradford Bemiss (principal investigator)

• Active, not recruiting

  A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

  NCT05996471· Phase 2· ViiV Healthcare· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Al Benson Iii (principal investigator)

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD2 recruiting
• HIV2 recruiting
• Colorectal cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

  NCT05274750· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

  NCT03574779· Phase 2· Tesaro, Inc.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

  NCT03525678· Phase 2· GlaxoSmithKline· Source

• Completed

  Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

  NCT01729455· GlaxoSmithKline· Source